TSHA Q1 2025 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-32.5% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$21M-930.5% margin

Net Income

-$22M-935.2% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+13.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$138M

Total Liabilities

$83M

Stockholders' Equity

$55M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-32.5%
Gross Profit	$2M	$3M	-32.5%
Operating Income	-$21M	-$24M	+12.0%
Net Income	-$22M	-$24M	+10.5%